CN114042042B - W/O/W type temperature-sensitive embolic agent - Google Patents
W/O/W type temperature-sensitive embolic agent Download PDFInfo
- Publication number
- CN114042042B CN114042042B CN202111432174.1A CN202111432174A CN114042042B CN 114042042 B CN114042042 B CN 114042042B CN 202111432174 A CN202111432174 A CN 202111432174A CN 114042042 B CN114042042 B CN 114042042B
- Authority
- CN
- China
- Prior art keywords
- sensitive
- temperature
- phase
- embolic agent
- developer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003073 embolic effect Effects 0.000 title claims abstract description 100
- 239000012071 phase Substances 0.000 claims abstract description 147
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 75
- 239000008346 aqueous phase Substances 0.000 claims abstract description 19
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229940127089 cytotoxic agent Drugs 0.000 claims description 18
- 239000004094 surface-active agent Substances 0.000 claims description 16
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical group C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 14
- 229960004359 iodixanol Drugs 0.000 claims description 8
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 8
- 229960001025 iohexol Drugs 0.000 claims description 8
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 8
- 229960004647 iopamidol Drugs 0.000 claims description 8
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 abstract description 16
- 230000008859 change Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 63
- 235000019198 oils Nutrition 0.000 description 63
- 239000000203 mixture Substances 0.000 description 38
- 238000002360 preparation method Methods 0.000 description 21
- 239000000499 gel Substances 0.000 description 17
- 238000002156 mixing Methods 0.000 description 17
- 238000004945 emulsification Methods 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 11
- 230000001804 emulsifying effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000010008 shearing Methods 0.000 description 10
- 208000005189 Embolism Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000004971 Cross linker Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 5
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- LEJBBGNFPAFPKQ-UHFFFAOYSA-N 2-(2-prop-2-enoyloxyethoxy)ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOC(=O)C=C LEJBBGNFPAFPKQ-UHFFFAOYSA-N 0.000 description 4
- INQDDHNZXOAFFD-UHFFFAOYSA-N 2-[2-(2-prop-2-enoyloxyethoxy)ethoxy]ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOCCOC(=O)C=C INQDDHNZXOAFFD-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000010102 embolization Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 2
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical group OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- IIYYSVCDYLYLRI-UHFFFAOYSA-N NC(=O)C=CCCCC=CC(N)=O Chemical compound NC(=O)C=CCCCC=CC(N)=O IIYYSVCDYLYLRI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000010108 arterial embolization Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- AYGYHGXUJBFUJU-UHFFFAOYSA-N n-[2-(prop-2-enoylamino)ethyl]prop-2-enamide Chemical compound C=CC(=O)NCCNC(=O)C=C AYGYHGXUJBFUJU-UHFFFAOYSA-N 0.000 description 1
- GJQRYIOSVPEUQJ-UHFFFAOYSA-N n-[3-(prop-2-enoylamino)propyl]prop-2-enamide Chemical compound C=CC(=O)NCCCNC(=O)C=C GJQRYIOSVPEUQJ-UHFFFAOYSA-N 0.000 description 1
- WDFKEEALECCKTJ-UHFFFAOYSA-N n-propylprop-2-enamide Chemical compound CCCNC(=O)C=C WDFKEEALECCKTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111432174.1A CN114042042B (en) | 2021-11-29 | 2021-11-29 | W/O/W type temperature-sensitive embolic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111432174.1A CN114042042B (en) | 2021-11-29 | 2021-11-29 | W/O/W type temperature-sensitive embolic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114042042A CN114042042A (en) | 2022-02-15 |
CN114042042B true CN114042042B (en) | 2023-07-25 |
Family
ID=80211517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111432174.1A Active CN114042042B (en) | 2021-11-29 | 2021-11-29 | W/O/W type temperature-sensitive embolic agent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114042042B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997036576A1 (en) * | 1996-04-01 | 1997-10-09 | Korea Institute Of Science And Technology | Preparation method of emulsion for chemoembolization |
WO2003022264A1 (en) * | 2001-09-13 | 2003-03-20 | Korea Institute Of Science And Technology | Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof |
CN1923303A (en) * | 2006-09-15 | 2007-03-07 | 华中科技大学 | Temperature sensing nano gel system for blood vessel embolism material |
CN101690831A (en) * | 2009-07-31 | 2010-04-07 | 华中科技大学 | Temperature-sensitive nano-gel vascular embolic materials, preparation method and application thereof |
CN107261197A (en) * | 2017-07-12 | 2017-10-20 | 安疗生命科学(武汉)有限公司 | One kind emulsification lipiodol vascular suppository material and its preparation method and application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106334213B (en) * | 2016-08-31 | 2019-07-26 | 安疗生命科学(武汉)有限公司 | A kind of vascular suppository material, preparation method and the purposes in medicine preparation |
-
2021
- 2021-11-29 CN CN202111432174.1A patent/CN114042042B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997036576A1 (en) * | 1996-04-01 | 1997-10-09 | Korea Institute Of Science And Technology | Preparation method of emulsion for chemoembolization |
WO2003022264A1 (en) * | 2001-09-13 | 2003-03-20 | Korea Institute Of Science And Technology | Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof |
CN1923303A (en) * | 2006-09-15 | 2007-03-07 | 华中科技大学 | Temperature sensing nano gel system for blood vessel embolism material |
CN101690831A (en) * | 2009-07-31 | 2010-04-07 | 华中科技大学 | Temperature-sensitive nano-gel vascular embolic materials, preparation method and application thereof |
CN107261197A (en) * | 2017-07-12 | 2017-10-20 | 安疗生命科学(武汉)有限公司 | One kind emulsification lipiodol vascular suppository material and its preparation method and application |
Non-Patent Citations (2)
Title |
---|
Permanent and Peripheral Embolization: Temperature-Sensitive p( N -Isopropylacrylamide- co -butyl Methylacrylate) Nanogel as a Novel Blood-Vessel-Embolic Material in the Interventional Therapy of Liver Tumors;Yanbing Zhao等;Advanced Functional Materials(第第21期期);第2035-2042页 * |
可显影原位凝胶化温敏纳米凝胶的制备及性能;王芹;徐辉碧;杨祥良;杨亚江;;医药导报(第10期);第1243-1247页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114042042A (en) | 2022-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9439861B2 (en) | Microspheres useful for therapeutic vascular embolization | |
Li et al. | Macromolecular ligands for gadolinium MRI contrast agents | |
CN100579586C (en) | Bone cement compositions | |
CN100502957C (en) | Temperature sensing nano gel system for blood vessel embolism material | |
CN114099764B (en) | Preparation method of W/O/W type temperature-sensitive embolic agent | |
CN110200937B (en) | Preparation method of porous hybrid microspheres with slow release performance | |
Lu et al. | Facile Synthesis of Weakly Ferromagnetic Organogadolinium Macrochelates‐Based T1‐Weighted Magnetic Resonance Imaging Contrast Agents | |
Zhang et al. | A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization | |
CN114042042B (en) | W/O/W type temperature-sensitive embolic agent | |
CN100544713C (en) | Chemoembolization blend compositions, the water-in-oil emulsion of said composition and their manufacture method of paclitaxel | |
CN106334213A (en) | Blood vessel embolism material as well as preparation method and application thereof to medicine preparation | |
Gervits et al. | A facile method of preparation of polymer-stabilized perfluorocarbon nanoparticles with enhanced contrast for molecular magnetic resonance imaging | |
CN105288662A (en) | T1-T2 dual-mode MRI contrast medium and preparation method and application thereof | |
Vogt et al. | Microfluidic fabrication of imageable and resorbable polyethylene glycol microspheres for catheter embolization | |
Zhou et al. | Temperature sensitive nanogels for real-time imaging during transcatheter arterial embolization | |
CN114377192B (en) | Preparation method of embolism material | |
JP2007161683A (en) | Method for producing emulsified liquid | |
CN103341182B (en) | Developing foam hardening agent for treating venous malformations and preparation method thereof | |
CN114470304B (en) | Chemoembolization composition and application thereof | |
CN1326890C (en) | Process for preparing vinylamide polymers for use in skin and hair compositions | |
JP2912683B2 (en) | Highly water-absorbing composition with low water solubility | |
CN108452326B (en) | Nano-particles with core-shell structure, preparation method and application | |
CN116271187A (en) | Bimodal developing temperature-sensitive Pickering emulsion interventional embolic material, and preparation method and application thereof | |
CN101962464A (en) | Method for preparing calcium alginate microspheres with temperature response performance | |
CN104382885A (en) | Hydrogel plaster and production method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230810 Address after: 510700 Room 202, building D, No. 136, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangdong Guangna Technology Development Co.,Ltd. Patentee after: Guangzhou Anbo Consulting Partnership (L.P.) Address before: 510000 Room 201, building D, 136 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangdong Guangdong Guangdong Hong Kong Macao Dawan District National Nanotechnology Innovation Research Institute |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231109 Address after: 510700 room 1003, building D, No. 136, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangdong Guangna Anyu Technology Co.,Ltd. Address before: 510700 Room 202, building D, No. 136, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangdong Guangna Technology Development Co.,Ltd. Patentee before: Guangzhou Anbo Consulting Partnership (L.P.) |
|
TR01 | Transfer of patent right |